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iomaterials for the
reatment of Myocardial Infarction
aren L. Christman, PHD,* Randall J. Lee, MD, PHD*†‡
erkeley and San Francisco, California
For nearly a decade, researchers have investigated the possibility of cell transplantation for
cardiac repair. More recently, the emerging fields of tissue engineering and biomaterials have
begun to provide potential treatments. Tissue engineering approaches are designed to repair
lost or damaged tissue through the use of growth factors, cellular transplantation, and
biomaterial scaffolds. There are currently 3 biomaterial approaches for the treatment of
myocardial infarction (MI). The first involves polymeric left ventricular restraints in the
prevention of heart failure. The second utilizes in vitro engineered cardiac tissue, which is
subsequently implanted in vivo. The final approach entails injecting cells and/or a scaffold into
the myocardium to create in situ engineered cardiac tissue. This review gives an overview of
the current progress in the growing field of biomaterials for the treatment of MI. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.005Coll Cardiol 2006;48:907–13) © 2006 by the American College of Cardiology Foundation
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peart failure after a myocardial infarction (MI) is often
rogressive. After death of the cardiomyocytes, macrophages,
onocytes, and neutrophils migrate into the infarct area,
nitiating the inflammatory response. Infarct expansion then
egins to occur because of the activation of matrix metallopro-
eases (MMPs), which degrade the extracellular matrix and
esult in myocyte slippage. This weakening of the collagen
caffold results in wall thinning and ventricular dilation. After
he initial inflammatory phase, there is an increase in fibrillar,
ross-linked collagen deposition, which resists deformation
nd rupture (1). Evidence suggests that the death of cardio-
yocytes results in negative left ventricular (LV) remodeling,
hich leads to increased wall stress in the remaining viable
yocardium. This process results in a sequence of molecular,
ellular, and physiological responses that lead to LV dilation. It
s suggested that LV remodeling may contribute independently
o the progression of heart failure (2).
Cellular transplantation, LV restraint devices, and tissue
ngineering approaches have emerged as possible alternatives
o heart transplantation for the treatment of damaged myocar-
ium (Fig. 1). Initial studies focused on the injection of viable
ells directly into the infarcted myocardium, a technique which
as been termed cellular cardiomyoplasty. More recent ap-
roaches include the use of in vitro engineered tissue, which is
ultured in vitro and then implanted in vivo, and in situ engi-
eered tissue, which is injected directly into the myocardium.
olymer meshes have also been utilized to prevent LV expan-
ion. This review focuses on the current advances and progress
n the use biomaterials for treatment of MI (Table 1). Bioma-
erial treatments that have been examined in vivo are covered.
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o prevent the negative LV remodeling and LV dilation
ssociated with MI (2), many studies have examined the use
f biomaterial supports to restrain the LV. Kelley et al. (3)
rst demonstrated that restraining infarct expansion pre-
ents a decline in cardiac function after an anteroapical MI.
poly(propylene) (Marlex) mesh was sutured onto the
yocardium at the location of a subsequently induced MI.
estraining the infarct wall preserved both LV geometry
nd cardiac function. Moreover, Bowen et al. (4) demon-
trated that the poly(propylene) restraint increased collagen
nd reduced MMP-1 and -2 activity in the border-zone
yocardium; however, both matrix components were un-
hanged within the infarct. Although Moainie et al. (5)
eported reduced ischemic mitral regurgitation in a postero-
ateral MI model, the LV volume of animals treated with
he Marlex mesh was not statistically different from control
nimals. A Marlex mesh covering the infarcted area was also
ompared to a Merselene (knitted polyester) mesh that
rapped around the LV. Enomoto et al. (6) reported that
rapping of the LV improved remodeling compared to the
esh, which covered only the infarcted area, indicating that
tiffening only the infarct may not be sufficient.
Another type of LV restraint consisting of a knitted
olyester mesh has been developed by Acorn Cardiovascular
nc. (St. Paul, Minnesota) The cardiac support device
CSD), which is fitted around both ventricles, was shown to
ecrease LV end-diastolic volume, myocyte hypertrophy,
nd interstitial fibrosis, as well as increase fractional short-
ning, in a study by Chaudhry et al. (7) using a canine
hronic heart failure model. Saavedra et al. (8) further
emonstrated that the CSD induced reverse remodeling, as
ndicated by decreased LV volume and a shifted end-systolic
ressure-volume relation. Pilla et al. (9) also showed a
ecrease in LV volume and an increased ejection fraction
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emonstrated similar effects in a canine chronic heart failure
odel, along with reduction of myocyte hypertrophy,
own-regulation of stretch response proteins, and improved
arcoplasmic reticulum calcium cycling. In an effort to more
ully decipher the mechanisms behind the CSD treatment,
lom et al. (11) reported a normalized myocyte beta-
drenergic response, reduced myocyte length, increased
ollagen content, and decreased MMP-9 in a sheep MI
odel. Clinical studies have also demonstrated the effec-
iveness of an LV restraint in humans. Konertz et al. (12)
eported an improved ejection fraction and reduced LV
olume in 27 patients suffering from heart failure 3 and 6
onths after receiving a CSD. Franco-Cereceda et al. (13)
lso reported increased LV function and decreased LV
olume in a trial with 8 patients with dilated cardiomyop-
thy. The length of the study was between 12 and 24
onths. Olsson et al. (14) demonstrated continued, gradual
mprovement in LV volume and function in 12 patients
Abbreviations and Acronyms
CSD  cardiac support device
LV  left ventricle
MI  myocardial infarction
MMP  matrix metalloprotease
PNIPAAM  poly(N-isopropylacrylamide)
igure 1. Strategies for treatment of myocardial infarction using biomateria
f myocardial infarction. Polymer meshes can be sutured around the heart
ngineered tissue involves culturing cells on a biomaterial scaffold in vitro a
issue can be achieved by injecting a biomaterial alone (d), or using an injectable s
r proteins (e).ith dilated cardiomyopathy; however, they also reported
ight ventricular dysfunction and no improvement in cardiac
utput. Acorn’s pivotal clinical trial encompassing 300
atients initially reported that the CSD reduced LV dia-
tolic volume, improved patient quality of life, and reduced
he likelihood of additional cardiac procedures (15). How-
ver, the significance of the study has been criticized because
f the partial recruitment of patients in an unblinded
ashion, the influence of missing data, and the decrease in
eneficial effects when patients undergoing concomitant
itral valve replacement were separated from the analysis.
Studies examining epicardial polymeric LV restraints
ave had encouraging results; however, a major drawback
ith this approach is the surgical procedure required for
mplantation. There are also some conflicting results as to
he real benefit of the CSD in clinical trials, where some
easures of cardiac function are improved, while others
emain unchanged or deteriorate. Therefore, the results
hould be taken with some caution, and there exists a need
or more long-term results and a more thorough analysis of
he exact mechanism behind LV restraint.
N VITRO ENGINEERED MYOCARDIAL TISSUE
issue engineering approaches are designed to repair lost or
amaged tissue through the use of cellular transplantation
nd biomaterial scaffolds. Numerous studies have examined
date, 3 different biomaterial approaches are being examined for treatment
e as a left ventricular (LV) restraint (a) to preserve LV geometry. In vitro
en implanting the tissue onto the epicardial surface (b). In situ engineeredls. To
for us
nd thcaffold as a delivery vehicle for cells (c) or therapeutic agents such as genes
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September 5, 2006:907–13 Biomaterials for Treatment of MIifferent scaffolds as well as various culture conditions for
reating in vitro engineered myocardial tissue (15–25).
hose that have been examined in vivo are discussed in this
eview. Li et al. (26) first demonstrated the transplantation
f cells in a biomaterial scaffold for the treatment of
yocardial scar tissue. They reported the survival of fetal
ardiomyocytes that were seeded onto a biodegradable
elatin mesh in vitro and implanted onto the myocardial
urface in a cryoinjury model; however, the cell seeded grafts
id not improve cardiac function. Leor et al. (27) reported
oth survival and preservation of cardiac function with fetal
ardiomyocytes seeded onto an alginate scaffold, which was
ubsequently implanted in a rat MI model. The grafts were
ound to be vascularized and the scaffold was completely
egraded after 2 months; however, only a small portion of
he graft consisted of myofibers. Transplantation of the
caffold alone was not examined, and thus it is unknown
hether improvement of cardiac function was a result of
mplantation of the biomaterial or cell transplantation.
ellar et al. (28) also employed a pre-formed scaffold by
sing the commercially available Dermagraft, which con-
ains human dermal fibroblasts cultured on a knitted poly
glycolide)/poly(lactide) mesh. Transplantation of the Der-
agraft onto the LV resulted in significantly higher ejection
ractions compared to infarcted mice that received no
reatment.
Rather than seed cells onto a pre-formed scaffold, Zim-
ermann et al. (29) combined neonatal cardiomyocytes
ith liquid collagen type I, matrigel, and cell culture
edium and then pipetted the mixture into molds to form
he desired shape. Upon transplantation onto the epicardial
urface of uninjured hearts, the engineered tissue was
ontractile in vivo up to 8 weeks and was observed to be
oth vascularized and innervated. In this first study, the
able 1. Biomaterials for Treatment of Myocardial Infarction
Material
eft ventricular restraint
Polypropylene Alone
Polyester Alone
n vitro engineered tissue
Gelatin Alone or with feta
Alginate With fetal cardiom
Poly(glycolide)/poly(lactide) With dermal fibro
Collagen type I and matrigel With neonatal car
PTFE, PLA mesh, collagen type I, and matrigel Alone or with bon
Collagen type I Alone or with em
PNIPAAM (cell culture dish) Cell sheet of neon
n situ engineered tissue
Fibrin Alone, with skelet
or pleiotrophin
Collagen Alone or with bon
Alginate Alone
Matrigel Alone or with em
Collagen type I and matrigel Alone or with neo
Self-assembling peptides Alone, with neon
Gelatin With basic fibrob
LA  poly(L-lactic) acid; PNIPAAM  poly(N-isopropylacrylamide); PTFE  pingle-muscle bundles in the engineered tissue did not dncrease above 100 m (30), as seen with many in vitro
ngineered tissues. Yet, in a more recent study, this group
eported 450-m-thick, newly formed myocardium using
his approach, which was shown to improve systolic and
iastolic function in rats. Five circular grafts were stacked
rosswise to obtain grafts of 1 to 4 mm in thickness that
ere subsequently transplanted onto the epicardial surface
f the infarct (31). Although it was not reported, necrosis
ithin the grafts likely occurred because of the significant
ecrease in thickness after transplantation. Grafts were
ultured with increased ambient oxygen and insulin, which
ay have allowed for the formation of in vitro tissue thicker
han the typical 100 m.
Krupnick et al. (32) also combined cells with a collagen
nd matrigel mixture. Bone marrow-derived mesenchymal
rogenitor cells were first suspended in the gel, then seeded
nto a porous poly(L-lactic acid) non-woven mesh, and
nally reinforced with a layer of poly(tetrafluoroethylene).
nstead of implanting the engineered tissue on the epicardial
urface, they sutured it into the infarct wall after a ventric-
lotomy. Aneurysmal dilation did not occur with this
ulti-material scaffold. Kofidis et al. (33) mixed embryonic
tem cells with collagen type I to form an in vitro tissue
onstruct, which was subsequently implanted into the in-
arct wall by surgically creating an intramural pouch in a rat
eterotopic heart transplant model. Transplanted cells
ormed viable grafts that prevented infarct wall thinning and
mproved fractional shortening compared to animals that
eceived either the scaffold without cells or no treatment.
Yamada et al. (34) and Okano et al. (35) have
eveloped a unique approach for utilizing a biomaterial
or the creation of patches of cardiac tissue in vitro. They
tilized a temperature-responsive polymer, poly(N-
sopropylacrylamide) (PNIPAAM), which is slightly hy-
Transplantation Reference
3–6
7–14
iomyocytes 27
tes 28
29
yocytes 30,31
rrow-derived mesenchymal progenitor cells 32
ic stem cells 33
ardiomyocytes or adipose-derived mesenchymal stem cells 36,37
oblasts, bone marrow mononuclear cells,
id
45–50,59
rrow cells 48,51,52
53
ic stem cells 48,54,55
cardiomyocytes 56
rdiomyocytes, or with platelet-derived growth factor BB 57,60
owth factor 58
rafluoroethylene).l card
yocy
blasts
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Biomaterials for Treatment of MI September 5, 2006:907–13hilic and cell-resistant at 32°C because of rapid hydration
nd swelling. Tissue culture plates were coated with
NIPAAM and subsequently seeded with neonatal cardio-
yocytes. Once the cells formed a monolayer, the temper-
ture was dropped and the cell sheet was removed intact.
oth cell-to-cell junctions and adhesive proteins within the
onolayers are preserved, unlike with enzymatic digestion
36). Up to 6 sheets (100 m) may be layered upon each
ther to create a 3-dimensional pulsatile cardiac tissue
onstruct without resulting in a necrotic core. More recently,
iyahara et al. (37) transplanted monolayers of adipose
issue-derived mesenchymal stem cells using this cell-sheet
echnology, which resulted in improved fractional shorten-
ng and infarct wall thickness. After 4 weeks, the monolay-
rs had expanded in situ to produce 600-m-thick tissue
here it was transplanted over the infarct scar. The newly
ormed tissue consisted of neovasculature, undifferentiated
esenchymal stem cells, and a few cardiomyocytes.
As seen with other in vitro tissue engineering approaches,
he majority of external myocardial tissue constructs are
imited to a thickness of 100 m or approximately 6
ardiomyocytes. Studies by both Zimmermann et al. (29–
1) and Miyahara et al. (37) demonstrated tissue of approx-
mately one-half a millimeter in thickness in vivo. Although
mproved culture conditions were attributed to the thicker
issue in the study by Zimmermann et al. (29–31), Miya-
ara et al. (37) transplanted a cell monolayer that then
xpanded to form a larger graft in vivo. The monolayer of
esenchymal stem cells produced only a few cardiomyo-
ytes, but this study does demonstrate the in situ expansion
apabilities of stem cells in the myocardium. Although these
tudies offer the hope of regenerating sizable constructs
sing an in vitro approach, the current thickness of half a
illimeter is unlikely to produce noticeable changes in
uman myocardium, which is significantly larger than the
at myocardium. Therefore, developing an in vitro cardiac
issue construct for humans using in vitro approaches is
urrently a major obstacle.
N SITU ENGINEERED MYOCARDIAL TISSUE
ellular cardiomyoplasty may be considered the first exam-
le of in situ cardiac tissue engineering. Cellular cardiomy-
plasty involves the transplantation of viable cells to replace
ecrotic cardiomyocytes. Although studies have shown
ome improvement in cardiac performance by using cellular
ardiomyoplasty, there are several problems associated with
his technique. The current transplantation techniques in-
olve the administration of cells in an aqueous solution
dministered intravenously, intracoronary or directly in-
ected into the myocardium; however, the techniques are
lagued by limited cell retention and transplant survival
38–41). When reported, the number of animals receiving
uccessful grafts is often low. Given that the cells are
njected in an ischemic region of the heart, there is also little
o no vasculature to supply the implanted cells. Cell survival ds thus limited by the lack of retention and vascularization.
nother problem associated with the current technique is
hat the cells are poorly distributed. Cross sections of the
nfarcted region show clusters of the implanted cells be-
ween scar tissue. Conduction through the infarcted region
hould thus still be a problem, since the cells are in isolated
reas and may lead to a proarrhythmic heterogeneous milieu
42). Furthermore, the typical injection technique involves
njection of cells in completely liquid solutions and does not
ive the transplanted cells a temporary matrix to which they
an attach. Cellular cardiomyoplasty does not involve the
se of biomaterials and is thus not fully covered in this
eview. Several excellent reviews exist that cover this topic in
etail (43,44).
The emerging field of tissue engineering has begun to
rovide promising alternatives to the typical cellular cardio-
yoplasty technique. Although in vitro-engineered myocar-
ial tissue has had some promising results, the limitations
escribed previously led to investigations of a different tissue
ngineering approach to cardiac repair. This in situ ap-
roach utilizes an injectable biomaterial to deliver cells
irectly into the infarct wall to increase cell survival.
njectable biomaterials can also be utilized in acellular
pproaches to support the LV wall and prevent the negative
emodeling after an MI, or for controlled delivery of
herapeutic genes and proteins to ischemic myocardium. An
njectable treatment is more minimally invasive than im-
lanting in vitro-engineered tissue or an epicardial patch,
nd is therefore more clinically appealing.
Christman et al. (45) were the first to demonstrate
mproved cell survival when transplanted cells are delivered
n an injectable scaffold compared to the typical cellular
ardiomyoplasty technique. The injectable biopolymer fi-
rin glue was also shown to induce neovascularization
ithin the ischemic myocardium and reduce infarct expan-
ion. More interesting is the observation that injection of
brin glue with or without skeletal myoblasts preserved LV
eometry and cardiac function in an acute MI model (46).
yu et al. (47) further demonstrated the beneficial effects of
n injectable fibrin glue scaffold by injecting bone marrow
ononuclear cells in the matrix. They likewise reported
nhanced neovascularization in ischemic myocardium,
hich was further confirmed by Huang et al. (48). Chek-
nov et al. (49) also demonstrated improved cardiac function
nd neovasculature with endothelial cells in a fibrin matrix
ompared to saline controls; however, injection of fibrin
lone or healthy endothelial cells alone was not examined.
herefore, it is difficult to conclude what caused the
mprovement. Recently, the use of fibrin glue for the
reatment of chronic aneurysms resulting from MI has been
nvestigated. Christman et al. demonstrated that the injec-
ion of fibrin glue into the aneurysm resulting from an MI
estored geometry of the LV and markedly improved LV
unction (50). Although the improvement of LV function
as not sustained at 5 weeks after the injection, arrest of LV
ilation and deterioration of LV function occurred.
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September 5, 2006:907–13 Biomaterials for Treatment of MIOther bio-derived materials have also been used for in
itu cardiac tissue engineering. Thompson et al. (51) dem-
nstrated successful injection of bone marrow cells in
ollagen into the myocardium via catheter; however, the
njection was done in uninjured hearts, and comparison to
ell injection in a liquid solution was not performed. Dai
t al. (52) also injected collagen into infarcted myocardium as
n acellular treatment. They reported improved LV geom-
try and cardiac function without increased vascularization
ompared to saline controls. In contrast, Huang et al. (48)
howed an increase in capillary density following injection
f collagen. Infiltration of myofibroblasts was also reported.
ecently, Leor et al. (53) have suggested that intramyocar-
ial injection of alginate induces neovascularization and
mproved LV function.
Kofidis et al. (54) examined an in situ approach using
atrigel to deliver mouse embryonic stem cells. An LV
ouch was formed, similarly to their study using an in vitro
pproach, and the gel was injected into the area. They
emonstrated improved LV function in those animals that
eceived the cell-matrigel mixture compared to those that
eceived either the biomaterial alone or cells in cell culture
edium. A further study used this approach to directly
nject the cells into infarcted murine myocardium (55).
oreover, Huang et al. (48) demonstrated increased vascu-
ature in infarcted myocardium after injection of matrigel.
hang et al. (56) used a mixture of matrigel, collagen, and
ell culture medium to deliver cardiomyocytes, similar to the
ystem used by Zimmermann et al. (29–31) in vitro, and
eported preserved LV geometry and cardiac function.
Davis et al. (57) developed a novel injectable scaffold for
he myocardium using self-assembling peptides, which form
anofibers upon injection, creating a microenvironment that
s suitable for cell and vessel ingrowth. After injection of the
eptides alone into the infarct, progenitor cells expressing
ndothelial cell markers and vascular smooth-muscle cells
ere recruited into the nanofibers. Neonatal cardiomyocytes
ere also injected with the nanofibers and were found to
nhance recruitment of endogenous cells. In contrast, little
ecruitment was seen in infarcted myocardium injected with
atrigel.
Taken together, these results suggest that matrigel may
e beneficial for delivering cells, but is not ideal for use alone
r as a scaffold that promotes in situ regeneration. Self-
ssembling peptides appear to have great promise in pro-
oting regeneration, but a suitable cell source for myocar-
ial regeneration is needed. Alginate, collagen, and fibrin
ave shown promise for cellular delivery and regeneration,
ut their long-term effects have not been examined.
hether their benefits will persist months and years after
he scaffold has degraded is unknown. Collagen and alginate
re also known to be mechanically unstable in vivo; thus,
hen used as a stand-alone treatment, an injectable polymer
hat is stiffer and either non-degradable or more slowly
egradable may be more beneficial. Such a scaffold may
revent heart failure by increasing the mechanical strength cf the infarct, thereby preventing remodeling and deterio-
ation of cardiac function in a similar fashion to LV
estraints. On the other hand, a polymer that is too stiff may
nduce diastolic dysfunction; therefore, the mechanical
roperties of the scaffold must be carefully examined.
While the typical tissue engineering approach involves a
iomaterial scaffold with cells, such biomaterials may also be
mployed as delivery vehicles for therapeutic genes or
roteins in order to stimulate tissue regeneration. Only a
ew studies to date have examined this in the myocardium.
wakura et al. (58) delivered basic fibroblast growth factor
ia injectable gelatin microspheres and reported increased
ngiogenesis as well as improved cardiac function. Christ-
an et al. (59) also increased neovascularization in ischemic
yocardium by delivering a plasmid encoding the angio-
enic growth factor pleiotrophin in fibrin glue. Finally,
sieh et al. (60) employed self-assembling peptides as a
elivery vehicle for platelet-derived growth factor-BB. They
eported sustained delivery for 14 days in infarcted myocar-
ium, which decreased cardiomyocyte death and preserved
ardiac function compared to either the peptides or the
rowth factor alone. They also demonstrated a reduction in
nfarct size. By injecting the therapeutic agent in a bioma-
erial, a more prolonged delivery profile can be achieved. A
caffold can also act as a gene-activated matrix to increase
he transfection efficiency of plasmid DNA (61).
UTURE DIRECTIONS AND CONCLUSIONS
any cell types and tissue engineering approaches have
mproved cardiac function in animal models; however, the
xact mechanisms of each approach are currently unknown.
here are still many questions and issues to be addressed
efore this technology can be safely applied to patients. For
nstance, finding the best cell source for cardiac repair
ontinues to remain a major obstacle because of the diffi-
ulty in isolating and expanding autologous sources, the
thical issues surrounding certain cell types, and the inability
f one cell source to fully replenish all necessary cell types.
urthermore, there is little data examining long-term re-
ults. Current studies often last 1 to 2 months, and thus may
ot be indicative of long-term outcomes.
The use of biomaterials for in situ cardiac tissue engineering
s being appreciated as either a stand-alone acellular solution
or cardiac repair or a hybrid therapy used in combination with
ells or therapeutic agents. Future studies are needed to
nvestigate whether biomaterials can be used to help repair
yocardial tissue after an acute ischemic insult and regenerate
yocardial tissue in a chronic scar. Biomaterials could be used
n situ to increase the wall thickness, restore the geometry, and
rovide structural support of an injured LV. The body would
e its own bioreactor and allow for infiltration of cells within
he scaffold matrix to regenerate myocardial muscle and blood
essels. Biomaterials have already been shown to recruit cells
nto injured myocardial tissue (48,57). To allow in situ myo-
ardial tissue engineering to become a viable option for the
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Biomaterials for Treatment of MI September 5, 2006:907–13reatment of myocardial injury, engineering of biomaterials to
pecifically influence the microenvironment of the myocardium
ill be required. Such materials should be designed to enhance
ecruitment of progenitor cells for myocardial muscle and
yocardial vasculature, and increase durability of improved LV
unction. Moreover, the formation of muscle bundles with
unctioning conductive tissue is a necessity.
Another important factor for the future success of bioma-
erial treatments in the myocardium is the control over the
issue response after implantation or injection. Introduction of
biomaterial into the body can result in a wide range of effects,
oth local and systemic (62). Implantation or injection results
n local injury, which can then initiate an inflammatory
esponse and foreign body reaction. Acute inflammation,
hich can last from minutes to days, is characterized by the
resence of edema and the migration of leukocytes into the
issue. Continued exposure to an inflammatory material can
ead to chronic inflammation, which involves the presence of
acrophages, monocytes, and lymphocytes. This can be caused
ot only by a non-biocompatible material, but also by a
aterial that is not properly secured in the body. Proliferation
f blood vessels and connective tissue also begins to occur at
his stage, which then leads to the formation of granulation
issue within 3 to 5 days of implantation. Implantation of a
iomaterial can also result in a foreign body reaction, which is
ndicated by the presence of foreign body giant cells. A greater
umber of these cells are often seen on the surfaces of rougher
r more porous materials compared to those with smooth
urfaces. The final phase of the foreign body reaction involves
brous tissue formation and encapsulation. A biomaterial’s
eaction at the implant site obviously must be considered when
hoosing a material for the heart, as chronic inflammation or
brous encapsulation would impede regeneration. More spe-
ific antigen-mediated responses can also occur and should be
onsidered when delivering bio-derived materials containing
omponents from other species. An excessive immune re-
ponse can even lead to hypersensitivity, which can result in
issue damage due to the release of intracellular chemicals, or
xcessive thrombus formation. Another concern over the
hoice of a biomaterial is its affinity for bacterial contamination
nd subsequent infection at the implant site. Likewise, the
bility to properly sterilize a biomaterial is critical.
The reaction of the body to a foreign material should thus be
eemed significant when designing biomaterial treatments for
he myocardium. The ability of cells to adhere, survive, and
igrate within a biomaterial scaffold should also be strongly
onsidered when trying to regenerate tissue. Synthetic hydro-
hobic materials will almost immediately adsorb proteins that
an then mediate cell attachment and spreading. Bio-derived
aterials such as fibrin glue and collagen natively contain
eptide binding sequences that cells can adhere to via integrins.
ynthetic materials can also be modified with these peptides as
ell as other molecules, in order to more closely mimic native
issue (63). These types of materials, termed biomimetics, have
ot yet been examined in the myocardium, but may provextremely useful for both improving cell adhesion and viability,
nd controlling the host response.
Because of the difficulties in finding the appropriate cell
ource, biomaterial treatments such as external LV restraints
r injectable polymers may be more easily realized in the
linic. With the aid of biomaterial scaffolds and a suitable
ell source, regenerated myocardium may be achieved. We
re thus optimistic that future studies will continue to
rovide more insights and that the field of biomaterials and
yocardial tissue engineering will bring new treatments for
hose patients with injured myocardium.
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